10:58 AM EST - Medicenna Therapeutics Corp. : Announced today that the American Society of Clinical Oncology decided to reverse its decision and to withdraw Medicenna’s abstract entitled “Results from ABILITY-1 Monotherapy Dose Escalation Study with MDNA11, an Engineered Long-acting IL-2 agonist, in patients with advanced solid tumors,” which had been initially selected for an oral podium presentation at ASCO’s 2024 Annual Meeting. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.02 at $2.49.
